Oxstones Investment Club™Several Central European countries are changing their policies on pharmaceutical reimbursements, which may have far reaching effects, especially in the market segments of generic and innovative drugs during the period from 2012-2014. Top manufacturers and distributors are searching for concrete details on the markets in Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria. They need comprehensive market analysis and forecasts to guide them in planning and strategic development in order to adapt to changing pricing, demand and growth prospects in the months ahead.
To meet industry requirements, PMR has compiled Generic and innovative drugs market in Central Europe 2012, Comparative analysis, reimbursement policies and development forecasts for 2012-2014, a new, all-inclusive guide to the regulatory framework and market demands of the region.
“Governments in several Central European countries have recently introduced solutions aimed at cutting their spending on pharmaceuticals. Examples of this are the Reimbursement Act in Poland, the structural reform programme based on the Szell Kalman Plan in Hungary, the amendment to the Act on Public Health Insurance in the Czech Republic and the act governing the scope and conditions of the reimbursement of drugs, medical appliances and dietary foods covered by public health insurance in Slovakia. These will have an impact on the generic and innovative drug segments in the countries in question and may lead to a rebalancing of power and influence within the pharmaceutical segments of each country.”
In order to locate and capitalize on new opportunities, you need direct access to the latest news, sharpest analysis, most reliable statistics and knowledgeable trends forecasting available. Read Generic and innovative drugs market in Central Europe 2012, Comparative analysis, reimbursement policies and development forecasts for 2012-2014 today, and refer to this new report from PMR on a regular basis as you monitor market expansion and contemplate new business strategies.
This market study delivers an overall assessment as well as data on size, value and share of each of these two segments in the covered countries. It details the specific regulatory policies in each of the countries and analyses the changes that will result from new pricing, reimbursement structures, expiry of drug patent procedures and data exclusivity periods. It synthesizes this new information to provide comparative analysis and produce detailed forecasts for the coming two years for market development, guiding professionals in their efforts to keep strategic planning in line with the shifting market.
Data includes pricing regulations for both reimbursed and non-reimbursed medications, VAT rates, reimbursement list changes, best selling products in the generic and innovative drug categories, and an inside look at the opinions of doctors and patients with regard to use of these products. Corporate profiles of the top generic and innovative drug manufacturers and producers in each country and for the region are presented.
The expansive scope of this document also includes the counterfeit drugs sub-segment, its market share and the policies of each government in dealing with the issue.
While preparing Generic and innovative drugs market in Central Europe 2012, Comparative analysis, reimbursement policies and development forecasts for 2012-2014, PMR’s expert analysts have consulted their most reliable sources and created a market guide that answers the questions of readers on all major issues with regard to both the current status and future progression of this dynamic marketplace.
For more information on the report please contact:
Marketing Department:
tel. /48/ 12 618 90 00
e-mail: marketing@pmrcorporate.com
Tags: best selling products in the generic and innovative drug categories, Bulgaria, Comparative analysis, Corporate profiles of the top generic and innovative drug manufacturers, counterfeit drugs sub-segment, drugs market, Generic and innovative drugs market in Central Europe 2012, Hungary, opinions of doctors and patients, poland, Reimbursement Act in Poland, reimbursement list changes, reimbursement policies and development forecasts for 2012-2014, romania, Slovakia, the amendment to the Act on Public Health Insurance in the Czech Republic, the Czech Republic, the structural reform programme based on the Szell Kalman Plan in Hungary, VAT rates